
To determine the zzso or recommended phase II dose, zzso zzso zzso zzso zzso and zzso effects of zzso in children with zzso or zzso solid tumors or zzso syndrome zzso 

zzso of children with solid tumors received zzso once daily for 21 days, every 28 days at dose levels of 15 to 70 zzso Children with zzso received a fixed dose of 5 zzso zzso for zzso and immune zzso were obtained in the first zzso 

zzso patients zzso solid zzso three zzso median age 16 years zzso 1 to 21 zzso were zzso and 42 were fully zzso for zzso One patient had a cerebrovascular zzso event of uncertain relationship to zzso zzso included zzso at 15 zzso zzso zzso and zzso at 40 zzso and zzso at 55 zzso At the highest dose level evaluated zzso zzso zero of six patients had zzso A zzso dose was not zzso No objective responses were zzso zzso studies zzso zzso 29) showed that clearance is faster in children younger than 12 years of zzso zzso studies zzso zzso 26) showed a significant increase in serum zzso zzso zzso zzso zzso zzso factor, natural killer zzso cells, zzso zzso and zzso activated killer zzso zzso and a significant decrease in zzso regulatory T zzso 

zzso is zzso at doses up to 70 zzso for 21 days in children with solid zzso Drug clearance in children younger than 12 years is faster than in adolescents and young zzso zzso significantly zzso cellular zzso including zzso and zzso zzso 

